Here, we report the investigation of specific biomarkers in relation to cisplatin (ERCC1), cetuximab (EGFR, pEGFR, pAkt, and pERK) and radiation (EGFR, pEGFR, pAkt, pERK, and ERCC1) treatments for six different HNSCC cell line xenografts. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.